Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer

Histone deacetylase 1 (HDAC1) is a co‐repressor involved in differentiation and proliferation control. It is upregulated in malignant compared to benign tissue, and targets a number of transcription factors including p53.

[1]  S. Schreiber,et al.  A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p , 1996, Science.

[2]  T. Heinzel,et al.  Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.

[3]  V. Speights,et al.  The dedifferentiation of metastatic prostate carcinoma. , 1989, British Journal of Cancer.

[4]  S. Parodi,et al.  Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer , 2000, Journal of cellular biochemistry.

[5]  J. Davie,et al.  Rapid Induction of Histone Hyperacetylation and Cellular Differentiation in Human Breast Tumor Cell Lines following Degradation of Histone Deacetylase-1* , 2000, The Journal of Biological Chemistry.

[6]  P. Brawn.  Histologic features of metastatic prostate cancer. , 1992, Human pathology.

[7]  N. Fusenig,et al.  Differentiation and tumor progression. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[8]  R. Dahiya,et al.  Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.

[9]  J. Swinnen,et al.  Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP , 1994, Molecular and Cellular Endocrinology.

[10]  E. Wintersberger,et al.  Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1 , 1999, Molecular and Cellular Biology.

[11]  P G Pelicci,et al.  Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.

[12]  J. McNeal,et al.  Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. , 1990, The Journal of urology.

[13]  T. H. van der Kwast,et al.  Androgen receptors in endocrine‐therapy‐resistant human prostate cancer , 1991, International journal of cancer.

[14]  U. Weidle,et al.  Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. , 2000, Anticancer research.

[15]  R. James,et al.  Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. , 1997, Cancer research.

[16]  K. Kuchler,et al.  Identification of mouse histone deacetylase 1 as a growth factor-inducible gene , 1997, Molecular and cellular biology.

[17]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[18]  L. Grochow,et al.  A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  T. Ekström,et al.  The human histone deacetylase family. , 2001, Experimental cell research.

[20]  J. Schalken,et al.  Expression of basal cell keratins in human prostate cancer metastases and cell lines , 2001, The Journal of pathology.

[21]  J. Swedlow,et al.  A workingperson's guide to deconvolution in light microscopy. , 2001, BioTechniques.

[22]  J. Cheville,et al.  Dedifferentiation in the metastatic progression of prostate carcinoma , 1999, Cancer.

[23]  T. Kouzarides,et al.  Regulation of E2F1 activity by acetylation , 2000, The EMBO journal.

[24]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[25]  J. Arends,et al.  Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low‐turnover tumors with distinct clinical outcome , 2003, Cancer.

[26]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.

[27]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[29]  C. Britten,et al.  A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  A. Bird,et al.  Histone deacetylases: silencers for hire. , 2000, Trends in biochemical sciences.

[31]  C. Allis,et al.  Roles of histone acetyltransferases and deacetylases in gene regulation , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[33]  J. Schalken,et al.  Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis , 2001, BJU international.

[34]  David E Neal,et al.  Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor* , 2002, The Journal of Biological Chemistry.

[35]  W. Fair,et al.  Prognostic significance of antigenic heterogeneity, gleason grade, and ploidy of lymph node metastases in patients with prostate cancer , 1992, The Prostate.

[36]  M. Nap,et al.  Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: An approach using multiparameter flow cytometry. , 2000, Gynecologic oncology.

[37]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[38]  G. Clark,et al.  Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. , 2001, Cytometry.

[39]  Julie A Hong,et al.  Induction of MAGE-3 expression in lung and esophageal cancer cells. , 2001, The Annals of thoracic surgery.

[40]  D. Neal,et al.  Regulation of FGF8 expression by the androgen receptor in human prostate cancer , 2002, Oncogene.

[41]  T. H. van der Kwast,et al.  Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. , 1998, Human pathology.

[42]  O. Cussenot,et al.  Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. , 1997, European journal of cancer.

[43]  J. Isaacs.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. , 1997, The American journal of pathology.

[44]  R. Nagle,et al.  Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. , 1987, Cancer research.

[45]  C. Tei,et al.  Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. , 2002, International journal of cancer.

[46]  M. Southey,et al.  Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.

[47]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[48]  S. Minucci,et al.  Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO , 1998, Molecular and Cellular Biology.

[49]  Brian H. Mayall,et al.  Guidelines for implementation of clinical DNA cytometry , 1993 .

[50]  Delin Chen,et al.  Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.

[51]  A. Norton,et al.  Brief, high‐temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues , 1994, The Journal of pathology.

[52]  J. Schalken,et al.  Demonstration of Intermediate Cells during Human Prostate Epithelial Differentiation In Situ and In Vitro Using Triple-Staining Confocal Scanning Microscopy , 2000, Laboratory Investigation.

[53]  K. Resing,et al.  Phosphatase Inhibition Leads to Histone Deacetylases 1 and 2 Phosphorylation and Disruption of Corepressor Interactions* , 2002, The Journal of Biological Chemistry.

[54]  Michael J Thun,et al.  Long‐term trends in cancer mortality in the United States, 1930–1998 , 2003, Cancer.

[55]  P. Brawn,et al.  Stage D1 prostate carcinoma the histologic appearance of nodal metastases and its relationship to survival , 1990, Cancer.

[56]  H. Kwon,et al.  Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues , 2001, Japanese journal of cancer research : Gann.

[57]  R. Schiltz,et al.  A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: inhibition of the myogenic program , 2001, The EMBO journal.